TY - JOUR
T1 - Biodegradable dental implants of ciprofloxacin β-cyclodextrin inclusion complex in the treatment of periodontitis
AU - Nagaraju, R.
AU - Udupa, N.
AU - Mathew, J.
AU - Varma, B. R.R.
N1 - cited By 4
PY - 1999
Y1 - 1999
N2 - Dental implants of ciprofloxacin β-cyclodextrin inclusion complex were formulated using poly (ε-caprolactone), a biodegradable polymer and evaluated. Clinical evaluation was carried out in ten patients with acute peridontitis. Various clinical parameters, viz. gingival index, plaque score, attachment gain, reduction in pocket depth were evaluated at 10, 20, 30, 40 days of treatment and compared with placebo as control. A significant (P < 0.0001) improvement in the healing of peridontal pockets treated with ciprofloxacin β-cyclodextrin implant was observed in most of the clinical parameters. Estimation of gingival crevicular fluids (GCF) for the drug content revealed that drug levels above the minimum inhibitory concentration (10.2 μg/mg) for many of the periodontal pathogens were maintained throughout the period of study (40 days). This confirms the clinical efficacy of the dose and the duration of the study. It was found that biodegradable carrier was better accepted than the non-biodegradable carriers reported earlier.
AB - Dental implants of ciprofloxacin β-cyclodextrin inclusion complex were formulated using poly (ε-caprolactone), a biodegradable polymer and evaluated. Clinical evaluation was carried out in ten patients with acute peridontitis. Various clinical parameters, viz. gingival index, plaque score, attachment gain, reduction in pocket depth were evaluated at 10, 20, 30, 40 days of treatment and compared with placebo as control. A significant (P < 0.0001) improvement in the healing of peridontal pockets treated with ciprofloxacin β-cyclodextrin implant was observed in most of the clinical parameters. Estimation of gingival crevicular fluids (GCF) for the drug content revealed that drug levels above the minimum inhibitory concentration (10.2 μg/mg) for many of the periodontal pathogens were maintained throughout the period of study (40 days). This confirms the clinical efficacy of the dose and the duration of the study. It was found that biodegradable carrier was better accepted than the non-biodegradable carriers reported earlier.
UR - http://www.scopus.com/inward/record.url?scp=0033054944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033054944&partnerID=8YFLogxK
M3 - Article
C2 - 10641162
AN - SCOPUS:0033054944
SN - 0019-5189
VL - 37
SP - 305
EP - 307
JO - Journal of scientific & industrial research. C. Biological sciences
JF - Journal of scientific & industrial research. C. Biological sciences
IS - 3
ER -